Jacobs Levy Equity Management’s Precision BioSciences DTIL Stock Holding History

Jacobs Levy Equity Management’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-47,485	Closed	-$486K	–	1001
2023 Q3	$486K	Buy	47,485 +21,462	+82%	+$330K	﹤0.01%	806
2023 Q2	$411K	Sell	26,023 -207	-0.8%	-$4.73K	﹤0.01%	848
2023 Q1	$593K	Buy	+26,230	New	+$864K	﹤0.01%	777
2021 Q4	–	Sell	-414	Closed	-$143K	–	995
2021 Q3	$143K	Hold	414	–	–	﹤0.01%	1007
2021 Q2	$156K	Hold	414	–	–	﹤0.01%	1000
2021 Q1	$129K	Sell	414 -2,387	-85%	-$836K	﹤0.01%	990
2020 Q4	$701K	Sell	2,801 -2,071	-43%	-$508K	0.01%	802
2020 Q3	$900K	Buy	4,872 +516	+12%	+$103K	0.01%	684
2020 Q2	$1.09M	Buy	4,356 +3,567	+452%	+$781K	0.01%	653
2020 Q1	$143K	Buy	+789	New	+$207K	﹤0.01%	930

Other funds holding DTIL

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MSAM

Moloney Securities Asset Management Manchester, Missouri $840M AUM 18.11% 1-Year Est. Return

Jacobs Levy Equity Management's DTIL Position: Q4 2023 in Review

Jacobs Levy Equity Management sold out of Precision BioSciences (DTIL) in Q4 2023, closing a stake of 47,485 shares — an estimated $486K sold.

Jacobs Levy Equity Management first reported a position in DTIL in Q1 2020 and held it in 10 quarters. The position peaked at $1.09M in Q2 2020. 65 funds tracked by Wall St. Rank hold DTIL as of Q4 2023.

Jacobs Levy Equity Management reported no remaining Precision BioSciences position as of Q4 2023 after selling out during the quarter.
Jacobs Levy Equity Management sold 47,485 Precision BioSciences shares in Q4 2023, an estimated $486K.
Jacobs Levy Equity Management first reported a position in Precision BioSciences in Q1 2020 and held it in 10 quarters.
Jacobs Levy Equity Management's Precision BioSciences position peaked at $1.09M in Q2 2020.
65 funds tracked by Wall St. Rank held Precision BioSciences as of Q4 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2023, filed 14 Feb 2024.